The Granisetron Transdermal Patch was administered by applying a single patch to the upper arm 24-48 hours before chemotherapy. The patch remained in place for 120 hours, delivering a controlled dose of 3.1 mg of granisetron every 24 hours to achieve a target plasma concentration of 2.2 ng/mL. The application process involved carefully removing the patch from its packaging, peeling off protective liners, and firmly pressing the adhesive side onto clean, dry skin. This transdermal system provided a convenient and effective way to prevent chemotherapy-induced nausea and vomiting by continuously delivering the 5HT3 inhibitor medication through the skin.
Key Points Explained:
-
Timing of Application
- The Granisetron Transdermal Patch was applied 24-48 hours before chemotherapy to ensure therapeutic levels were achieved when needed.
- This pre-treatment timing allowed the medication to reach steady-state plasma concentrations before chemotherapy began.
-
Application Site
- Patches were applied to the upper arm, chosen for its:
- Consistent skin permeability
- Low hair density
- Minimal interference with daily activities
- The site needed to be clean, dry, and free from lotions or oils.
- Patches were applied to the upper arm, chosen for its:
-
Patch Duration
- Each patch remained in place for 120 hours (5 days), providing:
- Continuous medication delivery
- Elimination of frequent oral dosing
- Stable plasma concentrations (target: 2.2 ng/mL)
- Each patch remained in place for 120 hours (5 days), providing:
-
Dosage Delivery
- The system delivered 3.1 mg/24 hours through:
- A multi-layer adhesive matrix
- Controlled-release technology
- Consistent transdermal absorption
- The system delivered 3.1 mg/24 hours through:
-
Step-by-Step Application
- Remove from foil pouch (never cut the patch)
- Peel plastic liner from printed side
- Bend patch to remove first adhesive film
- Apply sticky side to skin while holding remaining film
- Remove second film and press firmly
- Wash hands immediately
-
Mechanism of Action
- Granisetron blocks 5HT3 serotonin receptors to:
- Prevent nausea/vomiting signals
- Counteract chemotherapy side effects
- Maintain patient comfort
- Granisetron blocks 5HT3 serotonin receptors to:
-
Clinical Purpose
- Specifically designed for:
- Chemotherapy-induced nausea prevention
- Patients unable to take oral antiemetics
- Sustained protection during treatment cycles
- Specifically designed for:
The transdermal system's hands-off administration and prolonged effectiveness make it particularly valuable for patients undergoing challenging cancer treatments. Have you considered how such targeted delivery systems might reduce medication non-compliance in vulnerable populations? This technology exemplifies how pharmaceutical engineering can adapt to patient needs during difficult therapies.
Summary Table:
| Key Aspect | Details |
|---|---|
| Timing | Applied 24-48 hours before chemotherapy |
| Application Site | Upper arm (clean, dry skin) |
| Patch Duration | 120 hours (5 days) |
| Dosage Delivery | 3.1 mg/24 hours, target plasma concentration of 2.2 ng/mL |
| Mechanism of Action | Blocks 5HT3 serotonin receptors to prevent nausea/vomiting |
| Clinical Purpose | Chemotherapy-induced nausea prevention, especially for oral-intolerant patients |
Enhance patient comfort with reliable transdermal solutions!
At Enokon, we specialize in bulk manufacturing of high-quality transdermal patches, including innovative systems like the granisetron patch. Our expertise ensures:
- Precise dosing for consistent therapeutic effects
- Custom R&D for tailored transdermal solutions
- Scalable production for healthcare brands and distributors
Let’s collaborate to develop or supply transdermal systems that meet your patients' needs. Contact our team today to discuss partnerships or custom projects!
